| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 应用在聚氨酯聚合物中的活性胺催化剂 | CN97190650.5 | 1997-04-04 | CN1194595A | 1998-09-30 | 理查德M·格尔金; 凯·K·鲁宾逊 |
| 本发明提供应用于催化形成聚氨酯的胺/酰胺催化剂。所述胺/酰胺催化剂由于其与异氰酸酯的反应性具有低挥发性和良好的催化活性并具有结构(Ⅱ)。 | ||||||
| 2 | 轴向配体修饰的同核双金属化合物催化剂及其制法和应用 | CN201810544414.9 | 2018-05-30 | CN108579816A | 2018-09-28 | 张昉; 李震忠; 刘金秀 |
| 本发明公开了一种轴向配体修饰的同核双金属化合物催化剂及其制法和应用。所述轴向配体修饰的同核双金属化合物催化剂的制备方法包括：将包含Rh2(esp)2、轴向配体和有机溶剂的混合体系于室温下反应，获得轴向配体修饰的同核双金属化合物催化剂，其中，所述轴向配体包括含不饱和氮元素的有机配体。本发明提供的轴向配体修饰的同核双金属化合物催化剂在通过轴向配位调节双核铑金属化合物的反应活性和选择性，相比于改变桥联配体，操作方法更加简便，合成步骤更加简捷，配位后不但不影响Rh2(esp)2的反应活性，反而提高了催化合成N-H杂环丙烷化合物的反应选择性，而且也有普适性。 | ||||||
| 3 | 可后固化压敏粘合剂 | CN201480068808.1 | 2014-12-05 | CN105829468A | 2016-08-03 | M·里希特; K·翁弗豪; S·D·梅彻尼施; S·R·格布; P·比辛格尔 |
| 本公开涉及压敏粘合剂的可固化前体，其包含：a)(共)聚合材料，所述(共)聚合材料包含可(共)聚合材料的反应产物，所述可(共)聚合材料包含(甲基)丙烯酸酯单体；以及任选地，共聚单体，所述共聚单体具有烯键式不饱和基团并且不同于所述(甲基)丙烯酸酯单体；b)多官能氮丙啶固化剂；以及c)酸生成剂。本公开也涉及制造此类压敏粘合剂的方法及其用途。 | ||||||
| 4 | 轴向配体修饰的同核双金属化合物催化剂及其制法和应用 | CN201810544414.9 | 2018-05-30 | CN108579816B | 2021-06-08 | 张昉; 李震忠; 刘金秀 |
| 本发明公开了一种轴向配体修饰的同核双金属化合物催化剂及其制法和应用。所述轴向配体修饰的同核双金属化合物催化剂的制备方法包括：将包含Rh2(esp)2、轴向配体和有机溶剂的混合体系于室温下反应，获得轴向配体修饰的同核双金属化合物催化剂，其中，所述轴向配体包括含不饱和氮元素的有机配体。本发明提供的轴向配体修饰的同核双金属化合物催化剂在通过轴向配位调节双核铑金属化合物的反应活性和选择性，相比于改变桥联配体，操作方法更加简便，合成步骤更加简捷，配位后不但不影响Rh2(esp)2的反应活性，反而提高了催化合成N‑H杂环丙烷化合物的反应选择性，而且也有普适性。 | ||||||
| 5 | 用于脂质体中的有可裂解键的缀合物 | CN00807901.3 | 2000-04-21 | CN100512879C | 2009-07-15 | S·扎里普斯基; A·A·戈比曾 |
| 记载了一种疏水性部分-如脂质-的缀合物，通过可裂解的二硫苄基键与治疗药物连接。二硫苄基键会被温和的硫解所裂解，导致释放出原始状态的治疗剂。在非还原的条件下这种键是稳定的。可以将此缀合物引入到脂质体中，用于体内给药，并对体内内源性的还原条件产生反应，或对服用的外源性还原剂产生反应，从而释放治疗剂。 | ||||||
| 6 | Fluorine and sulfur-containing compositions | US459258 | 1974-04-08 | US3948887A | 1976-04-06 | Robert Bonner Hager; Sameeh Said Toukan |
| The invention concerns epoxides and alcohols of the structures ##EQU1## and[R.sub.f (CH.sub.2).sub.n SCH.sub.2 ].sub.2 CHOHand various derivatives thereof useful in leather and textile treatment. | ||||||
| 7 | Amide derivatives | US11176327 | 2005-07-08 | US20050245551A1 | 2005-11-03 | Dearg Brown |
| The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and carboxy; R3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino and N-(1-6C)alkyl-arylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. | ||||||
| 8 | Monomodal and polymodal catalyst supports and catalysts having narrow pore size distributions and their production | US711043 | 1996-09-10 | US5935897A | 1999-08-10 | Peter Trubenbach; Alfred Hagemeyer; Gunter Lauth; Uwe Dingerdissen; Franz Josef Brocker; Klemens Flick |
| Monomodal or polymodal catalyst supports or catalysts having a BET specific surface area of from 0.01 to 250 m.sup.2 /g and a monomodal or polymodal pore size distribution having a mean pore diameter of from 50 to 300,000 nm measured by the mercury pressure porosimetry method, whereina) from 10 to 95% of the pore volume is at from 0.2 to 100 times the mean pore diameter and/orb) from 10 to 80% of the pore volume is at from 0.8 to 100 times the mean pore diameter and/orc) from 50 to 95% of the pore volume is at from 0.2 to 1 times the mean pore diameter and/ord) from 50 to 80% of the pore volume is at from 0.8 to 1 times the mean pore diameter ande) the width at half height of the pore size distribution is less than 0.6 times the mean pore diameter, whichare useful for the preparation of chlorine from hydrogen chloride in a non-steady-state Deacon process, for the reaction of ethylbenzene to give styrene in a non-steady-state oxydehydrogenation, for preparing aziridine from ethanolamine, in reductions, hydrogenations, oxidations, dehydrogenations, acid- or base-catalyzed reactions or reactions in a fluidized bed, for removing combustion residues from diesel exhaust gases and for removing NO.sub.x from waste gases, in bioreactors together with bacteria and as biocatalyst supports with immobilized enzymes or microbes, and a process for producing said monomodal or polymodal catalyst support or catalyst. | ||||||
| 9 | Imidazole compounds useful in radiotherapy or chemotherapy and compositions | US792155 | 1985-10-28 | US4596817A | 1986-06-24 | Israr Ahmed; Gerald E. Adams; Ian J. Stratford |
| A chemopotentiating or radiation sensitizing compound of formula I ##STR1## in which formula: R.sub.1 represents hydrogen or an alkyl group;R.sub.2 -R.sub.5 represent hydrogen, alkyl aryl, aralkyl or alkaryl group; andn is 1 or 2 and process for producing. | ||||||
| 10 | Process for the manufacture of tetrasubstituted ureas | US22562572 | 1972-02-11 | US3904602A | 1975-09-09 | SOMLO TIBOR |
| A process for the manufacture of N,N,N'',N''-tetrasubstituted ureas of the general formula
in which R1 to R4 each represent an alkyl radical, with R1 and R2 and R3 and R4 in each case together with the nitrogen atom to which they are bonded, being able to form a heterocyclic ring which may optionally contain further hetero atoms, wherein N,Ndisubstituted carbamic acid halides of the formula in which R1 and R2 have the meaning given above and X represents a halogen atom, especially chlorine or bromine are reacted with a secondary amine and an inorganic base, preferably anhydrous ammonia and the new N,N,N'',N''-tetrasubstituted ureas. |
||||||
| 11 | 인산기-선택적인 형광 프로브를 이용한 포스파타제 활성 측정 방법 | KR1020080001394 | 2008-01-04 | KR100941679B1 | 2010-02-12 | 안대로; 신동윤; 안희철 |
| 본 발명은 인산기-선택적인 형광 프로브의 제조 방법에 관한 것으로서, 특히 특정 구조의 인산기 결합성 물질에 형광 물질을 공유 결합시킨 후, 생성 화합물을 금속 이온과 배위 결합시키는 것을 포함하는, 인산기-선택적인 형광 프로브의 제조 방법에 관한 것이다. 본 발명에 따라 제조된 인산기-선택적인 형광 프로브는 포스파타제 활성 측정 방법에 유용하게 이용될 수 있다. 포스파타제 (phosphatase), 탈인산화 반응 (dephosphorylation), CIP (calf intestinal alkaline phosphatase), 형광 편광도 (fluorescence polarization), 인산기-선택적인 프로브 (phosphate-specific probe). | ||||||
| 12 | Single mode or multiple mode catalyst carrier or catalyst, preparation of the same and production of chlorine | JP24231896 | 1996-09-12 | JPH09117674A | 1997-05-06 | PEETAA TORIYUUBENBATSUHA; ARUFUREETO HAAGEMAIAA; GIYUNTAA RAUTO; UUBUE DEINGAADEITSUSEN; FURANTSU YOOZEFU BURETSUKAA; KUREMENSU FURITSUKU |
| PROBLEM TO BE SOLVED: To obtain relatively high mechanical strength by specifying the average pore size of pores of a specified pore volume ratio in a single mode or multiple mode catalyst carrier or catalyst having a specified BET specific surface area and an average pore size. SOLUTION: In a new improved single mode or multiple mode catalyst carrier or catalyst having single mode or multiple mode pore size distribution having a BET specific surface area of 0.01-250m/g and an average pore size of 300,000nm measured according to a mercury pressurization porosity measuring method, 10-95% of the pore volume is made 0.2-100 times the average pore diameter, Or 10-80% of the pore volume is made 0.8-100 times the average pore size, and/or 50-95% of the pore volume is made 0.8-1 time of the average pore size. Besides, the half value width of the pore side size distribution is made less than 0.6 time of the average pore size. COPYRIGHT: (C)1997,JPO | ||||||
| 13 | Mitomycin derivative | JP7566087 | 1987-03-28 | JPS63243084A | 1988-10-07 | KURODA TOKUYUKI; HISAMURA KOJI; SUGAYA TORU; OSAWA YUTAKA; UENO HIDEO; MATSUKUMA MASAO; MORIMOTO MAKOTO; ASHIZAWA TADASHI |
| NEW MATERIAL:A compound expressed by formula I {X represents O, S, Se or sulfoxide; R1 represents (substituted)lower alkyl, lower cycloalkyl, formula II [R' and R'' represent (substituted)lower alkyl or lower cycloalkyl], (substituted)aryl or (substituted)pyridyl; R<2> represents H, lower alkyl, lower cycloalkyl, (substituted)aralkyl, (substituted)alkanoyl, etc.; R3 represents H, methyl or acetyl; R4 represents H or methyl; R5 represents H or carbamoyl; - represents alpha-bond or beta-bond}. USE:An antitumor agent. PREPARATION:A compound expressed by formula III [R21 represents lower alkyl, lower cycloalkyl, (substituted)aralkyl or (substituted)alkanoyl, etc.] is reacted with compounds expressed by the formula R1X1X1R1 and the formula (R9)3P (R9 represents lower alkyl, phenyl or dimethylamino) to afford a compound expressed by formula I wherein the group X is X1 and the group R2 is R21. The compound expressed by formula III as a starting raw material is a novel substance and produced from mitomycins expressed by formula IV. | ||||||
| 14 | Selective immunosuppressive | JP22502385 | 1985-10-11 | JPS6287512A | 1987-04-22 | UUBUE BITSUKAA; BURUFU PAARUKE |
| 15 | Compound binding mitomycin with polysaccharide | JP17675683 | 1983-09-24 | JPS6067503A | 1985-04-17 | HASHIDA MITSURU; SEZAKI HITOSHI |
| PURPOSE: The titled compound that is obtained by allowing a mitomycin to bond with the spacers connecting to the hydroxyls of a polysaccharide, thus showing large duration of anticancer activity in blood and high transition into lymph in thoracic ducts. CONSTITUTION: A polysaccharide such as dextran, cellulose, agarose or alginic acid is allowed to react with a monohaloalkanoic acid which may be substituted with lower alkyl groups at any hydrogens in its alkylene chain of the formula Hal-(CH 2) nCO 2H (Hal is halogen; n is 3W7) in an aqueous solvent in the presence of an acid binder to prepare the intermediate bearing the spacer. Then, the reaction between the resultant intermediate and a mitomycin is carried out in an aqueous medium in the presence of a condensation agent to give the objective compound in which the polysaccharide and a mitomycin are bonded with a group of the formula (N is the nitrogen atom in the imino group of mitomycin; O is an oxygen atom in hydroxyl groups of the polysaccharide) which may be substituted at hydrogen atoms on the methylene groups with lower alkyls. COPYRIGHT: (C)1985,JPO&Japio | ||||||
| 16 | Novel mitomycin derivative | JP17675583 | 1983-09-24 | JPS6067502A | 1985-04-17 | MURANISHI SHIYOUZOU; SEZAKI HITOSHI |
| PURPOSE: The titled derivative that is obtained by reaction between a water- soluble polysaccharide with a spacer bonded and a mitomycin, thus being composed of a polysaccharide bonded through a spacer to a mitomycin and showing good transition to lymph and long activity duration. CONSTITUTION: A water-soluble polysaccharide such as dextran is dissolved in water and a cyan halide is added thereto, while the pH is maintained to 10.7. Then, the activated polysaccharide is allowed to react with an amino-fatty acid such as epsilon-amino-n-caproic acid as a spacer near pH 9, and a mitomycin is allowed to react with the polysaccharide bearing spacers in the presence of a condensation agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at a pH between 5 and 6 to give the objective substance. COPYRIGHT: (C)1985,JPO&Japio | ||||||
| 17 | Novel compound | JP12550277 | 1977-10-19 | JPS5461163A | 1979-05-17 | NAKAGAWA NOBUAKI; YAMAUCHI HIROYO; KITAZAWA SHIYUUICHI; NODA TOSHIHARU; OOKAWA KENJI |
| NEW MATERIAL:Compounds of formula I: (R 1 is H or lower alkyl group; R 2 is H or amino protective group; R 3 is antigenic molecule amino residue; antigenic molecule amino residue having terminal amino group). EXAMPLE: Aziryl-glycyl-insulin. USE: Intermediates for compounds usable in Enzymo-immuno assay, scarcely deteriorating the enzymic and immunological activites. No side reactions. PROCESS: Aziryl carboxylic acid derivatives of formula II: (R 2' is amino protective group; R 4 is active ester) are reacted with antigenic molecules corresponding to R 3, antigenic molecules, e.g. primary antibody, hapten, etc., or antigenic molecules having terminal amino groups, and, if necessary, with removal of R 2' to give the objective compounds of formula I. The enzymo-immuno assay compounds can be obtained by reacting compounds of formula I, wherein R 2 is H, with an enzyme COPYRIGHT: (C)1979,JPO&Japio | ||||||
| 18 | JPS5059365A - | JP11049273 | 1973-10-03 | JPS5059365A | 1975-05-22 | |
| 19 | JPS5013280B1 - | JP9292769 | 1969-11-21 | JPS5013280B1 | 1975-05-19 | |
| 20 | Hydroxylamines with hypoglycemic activity | US390955 | 1995-02-21 | US5545659A | 1996-08-13 | Miljenko Dumi c; Darko Fili c; Mladen Vinkovi c; Blanka Jamnicky; Mirela E skinja |
| Novel 1-(2-,3- or 4-hydroxylaminobenzensulfonyl-1a,2,6,6 a-tetrahydro-1H,4H-[1,3]-dioxepino[5,6-b]azirines with hypoglycemic activity are prepared by selective reduction of appropriate 1-(2-,3- or 4-nitrobenzenesulfonyl) derivatives. | ||||||
QQ群二维码
意见反馈
意见反馈